We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genomics and AI-Powered Urine Infectious Disease Test Addresses Critical Need for Complicated UTIs

By LabMedica International staff writers
Posted on 02 Jan 2025

Urinary tract infections (UTIs) are the most prevalent outpatient infection, affecting over 7 million patients annually, with women being disproportionately impacted. More...

UTIs can severely affect the quality of life and lead to significant health complications. Around 30% of sepsis cases stem from the urogenital tract, with immunocompromised patients being at a higher risk of developing urosepsis. Current diagnostic methods are slow and fail to detect many pathogens, including fastidious bacteria, anaerobes, and fungi. A new genomics-based urine assay using artificial intelligence (AI) now offers a faster, more accurate (97% sensitivity, 99% specificity), and comprehensive solution for identifying urogenital pathogens, including those often missed by traditional culture techniques.

The BIOTIA-ID urine NGS assay by Biotia (New York, NY, USA) combines AI and genomics, specifically shotgun metagenomic sequencing, to provide a comprehensive detection of pathogens, reducing false positives and overcoming the limitations of traditional methods such as culture, PCR, and targeted 16S amplicon next-generation sequencing (NGS), which frequently produce incomplete, unclear, or contradictory results. Powered by BIOTIA-DX software, this qualitative NGS-based in-vitro diagnostic test identifies clinically relevant urogenital pathogens from a database of over 7,000 clinically curated microbes. The test detects more than 30 pathogens known to cause UTIs, including fastidious bacteria, anaerobes, fungi, and polymicrobial infections.

BIOTIA-ID is designed specifically for high-risk patients with recurrent and complicated UTIs, serving as a reflex test for culture-negative specimens. This allows for a more targeted therapeutic approach based on the unique microbial profile of each patient’s sample. A recent clinical study showed the high performance of BIOTIA-ID, revealing that the assay identifies pathogens in 60% of urine samples where traditional culture methods fail. Alarmingly, 70% of these patients had previously been prescribed ineffective antimicrobials for the pathogens detected by BIOTIA-ID.

"Precision infectious disease diagnostics is not just about improving individual patient care; it is about transforming the healthcare landscape," said Dr. Niamh O'Hara, CEO and Co-Founder of Biotia. "By providing accurate, detailed, and timely information, we can move towards a future where treatment is truly personalized and public health is protected."

Related Links:
Biotia


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.